Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Health Care Costs | 2 | 2020 | 215 | 0.640 |
Why?
|
| Accountable Care Organizations | 1 | 2021 | 67 | 0.640 |
Why?
|
| Medicare | 2 | 2021 | 613 | 0.600 |
Why?
|
| Patient Readmission | 1 | 2021 | 429 | 0.520 |
Why?
|
| Algorithms | 2 | 2020 | 1005 | 0.470 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 844 | 0.380 |
Why?
|
| Medicare Part D | 4 | 2015 | 36 | 0.350 |
Why?
|
| Hospitalization | 6 | 2021 | 1364 | 0.320 |
Why?
|
| Activities of Daily Living | 3 | 2021 | 292 | 0.320 |
Why?
|
| Male | 31 | 2024 | 29989 | 0.280 |
Why?
|
| United States | 16 | 2021 | 7867 | 0.280 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 5493 | 0.270 |
Why?
|
| Prostatic Neoplasms | 2 | 2022 | 418 | 0.270 |
Why?
|
| Patient Compliance | 4 | 2010 | 360 | 0.270 |
Why?
|
| Aged | 23 | 2024 | 14511 | 0.260 |
Why?
|
| Female | 32 | 2024 | 33001 | 0.260 |
Why?
|
| Nursing Homes | 4 | 2021 | 672 | 0.240 |
Why?
|
| Physicians, Primary Care | 2 | 2017 | 78 | 0.240 |
Why?
|
| Early Detection of Cancer | 4 | 2022 | 324 | 0.240 |
Why?
|
| Breast Neoplasms | 5 | 2022 | 1208 | 0.230 |
Why?
|
| Gout | 4 | 2010 | 48 | 0.230 |
Why?
|
| Medication Adherence | 3 | 2011 | 204 | 0.220 |
Why?
|
| Homes for the Aged | 2 | 2020 | 161 | 0.220 |
Why?
|
| Humans | 39 | 2024 | 63607 | 0.220 |
Why?
|
| Inappropriate Prescribing | 1 | 2024 | 66 | 0.210 |
Why?
|
| Prostate-Specific Antigen | 2 | 2022 | 77 | 0.210 |
Why?
|
| Regression Analysis | 2 | 2020 | 499 | 0.190 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 99 | 0.190 |
Why?
|
| Dementia | 1 | 2024 | 262 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 456 | 0.170 |
Why?
|
| Fractures, Bone | 2 | 2013 | 143 | 0.170 |
Why?
|
| Kallikreins | 1 | 2020 | 8 | 0.170 |
Why?
|
| Diphosphonates | 2 | 2010 | 33 | 0.170 |
Why?
|
| Mobility Limitation | 1 | 2020 | 49 | 0.160 |
Why?
|
| Morbidity | 1 | 2020 | 113 | 0.160 |
Why?
|
| Vaccines | 1 | 2021 | 98 | 0.160 |
Why?
|
| Cystic Fibrosis | 2 | 2011 | 121 | 0.160 |
Why?
|
| Gout Suppressants | 2 | 2010 | 22 | 0.150 |
Why?
|
| Forecasting | 1 | 2020 | 233 | 0.150 |
Why?
|
| Middle Aged | 20 | 2024 | 17701 | 0.150 |
Why?
|
| Continuity of Patient Care | 2 | 2017 | 174 | 0.150 |
Why?
|
| Cardiovascular System | 1 | 2019 | 40 | 0.150 |
Why?
|
| Retrospective Studies | 7 | 2021 | 6691 | 0.140 |
Why?
|
| Attitude to Health | 1 | 2020 | 293 | 0.140 |
Why?
|
| Hospitals | 1 | 2021 | 394 | 0.140 |
Why?
|
| Electronic Health Records | 2 | 2020 | 361 | 0.140 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 2699 | 0.140 |
Why?
|
| Risk Factors | 4 | 2020 | 5365 | 0.130 |
Why?
|
| Physicians | 1 | 2022 | 475 | 0.130 |
Why?
|
| Reminder Systems | 1 | 2017 | 75 | 0.130 |
Why?
|
| Insurance, Health | 2 | 2014 | 151 | 0.120 |
Why?
|
| Antipsychotic Agents | 2 | 2024 | 301 | 0.120 |
Why?
|
| Vaccination | 3 | 2023 | 364 | 0.120 |
Why?
|
| Truth Disclosure | 1 | 2015 | 57 | 0.120 |
Why?
|
| Adult | 12 | 2024 | 16894 | 0.120 |
Why?
|
| Osteoporosis | 3 | 2010 | 106 | 0.120 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2019 | 361 | 0.110 |
Why?
|
| Longitudinal Studies | 5 | 2023 | 1258 | 0.110 |
Why?
|
| Papanicolaou Test | 1 | 2014 | 44 | 0.110 |
Why?
|
| Vaginal Smears | 1 | 2014 | 57 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2024 | 3304 | 0.110 |
Why?
|
| Health Literacy | 1 | 2014 | 85 | 0.100 |
Why?
|
| Bone Density Conservation Agents | 2 | 2010 | 44 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2013 | 518 | 0.100 |
Why?
|
| Medical Errors | 1 | 2015 | 196 | 0.100 |
Why?
|
| Smoking | 2 | 2009 | 866 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 142 | 0.100 |
Why?
|
| Health Status | 1 | 2015 | 443 | 0.100 |
Why?
|
| Heart Failure | 1 | 2020 | 915 | 0.100 |
Why?
|
| Databases, Factual | 5 | 2019 | 873 | 0.090 |
Why?
|
| Mammography | 2 | 2022 | 291 | 0.090 |
Why?
|
| Colonoscopy | 1 | 2012 | 100 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2017 | 696 | 0.090 |
Why?
|
| Drug Utilization | 2 | 2010 | 209 | 0.090 |
Why?
|
| Social Class | 1 | 2012 | 136 | 0.090 |
Why?
|
| Tobramycin | 1 | 2011 | 7 | 0.090 |
Why?
|
| Insurance | 1 | 2011 | 18 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 54 | 0.080 |
Why?
|
| Deductibles and Coinsurance | 1 | 2010 | 9 | 0.080 |
Why?
|
| Financing, Personal | 1 | 2010 | 23 | 0.080 |
Why?
|
| Health Services | 1 | 2011 | 82 | 0.080 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2011 | 108 | 0.080 |
Why?
|
| Bone Density | 1 | 2010 | 134 | 0.080 |
Why?
|
| Adolescent Behavior | 2 | 2009 | 194 | 0.080 |
Why?
|
| Survivors | 2 | 2013 | 177 | 0.080 |
Why?
|
| Bone Resorption | 1 | 2010 | 42 | 0.080 |
Why?
|
| Benzodiazepines | 1 | 2010 | 100 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 764 | 0.080 |
Why?
|
| Drugs, Generic | 1 | 2009 | 18 | 0.080 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2009 | 42 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2010 | 162 | 0.080 |
Why?
|
| Massachusetts | 3 | 2024 | 2075 | 0.080 |
Why?
|
| Hip Fractures | 1 | 2010 | 77 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2010 | 168 | 0.070 |
Why?
|
| Confidence Intervals | 4 | 2010 | 240 | 0.070 |
Why?
|
| Age Factors | 4 | 2020 | 1566 | 0.070 |
Why?
|
| Proportional Hazards Models | 4 | 2013 | 732 | 0.070 |
Why?
|
| Poverty | 1 | 2010 | 298 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2008 | 56 | 0.070 |
Why?
|
| Insurance Claim Review | 1 | 2007 | 76 | 0.060 |
Why?
|
| Health Maintenance Organizations | 1 | 2007 | 60 | 0.060 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 123 | 0.060 |
Why?
|
| Family | 1 | 2009 | 242 | 0.060 |
Why?
|
| Students | 1 | 2009 | 220 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 2464 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 541 | 0.060 |
Why?
|
| Pandemics | 2 | 2022 | 672 | 0.060 |
Why?
|
| Cohort Studies | 5 | 2011 | 2576 | 0.060 |
Why?
|
| Young Adult | 4 | 2024 | 4711 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2014 | 566 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2010 | 299 | 0.060 |
Why?
|
| Time Factors | 4 | 2017 | 3770 | 0.060 |
Why?
|
| Computer Communication Networks | 1 | 2005 | 13 | 0.060 |
Why?
|
| Adolescent | 6 | 2011 | 6257 | 0.060 |
Why?
|
| Cholinergic Antagonists | 1 | 2024 | 32 | 0.060 |
Why?
|
| Deprescriptions | 1 | 2024 | 25 | 0.060 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 66 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2005 | 66 | 0.050 |
Why?
|
| Medical Informatics | 1 | 2005 | 73 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 280 | 0.050 |
Why?
|
| Registries | 2 | 2005 | 892 | 0.050 |
Why?
|
| Trust | 1 | 2024 | 76 | 0.050 |
Why?
|
| Child | 5 | 2011 | 4534 | 0.050 |
Why?
|
| Health Services Research | 1 | 2005 | 270 | 0.050 |
Why?
|
| Risk Assessment | 4 | 2011 | 2081 | 0.050 |
Why?
|
| Patient Participation | 1 | 2024 | 230 | 0.050 |
Why?
|
| Intention | 1 | 2022 | 70 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2005 | 268 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 2588 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 477 | 0.040 |
Why?
|
| Mass Screening | 2 | 2022 | 691 | 0.040 |
Why?
|
| Michigan | 1 | 2020 | 43 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2020 | 61 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2020 | 75 | 0.040 |
Why?
|
| Allopurinol | 2 | 2010 | 15 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 112 | 0.040 |
Why?
|
| Uric Acid | 2 | 2010 | 47 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2020 | 177 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 61 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 135 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2020 | 305 | 0.030 |
Why?
|
| Peer Group | 2 | 2009 | 105 | 0.030 |
Why?
|
| Incidence | 2 | 2013 | 1384 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2010 | 768 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 722 | 0.030 |
Why?
|
| Perception | 2 | 2009 | 176 | 0.030 |
Why?
|
| Data Collection | 1 | 2019 | 384 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2010 | 938 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1121 | 0.030 |
Why?
|
| Survival Rate | 2 | 2013 | 853 | 0.030 |
Why?
|
| Tobacco Use Disorder | 2 | 2009 | 246 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2011 | 1999 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 48 | 0.030 |
Why?
|
| Prognosis | 2 | 2013 | 1748 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2015 | 126 | 0.030 |
Why?
|
| Neoplasms | 1 | 2005 | 1370 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2015 | 127 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2017 | 512 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 1096 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 244 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 421 | 0.020 |
Why?
|
| Deoxyribonuclease I | 1 | 2011 | 41 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 347 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 601 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2010 | 76 | 0.020 |
Why?
|
| Legislation, Drug | 1 | 2010 | 17 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 1 | 2010 | 32 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 486 | 0.020 |
Why?
|
| Colchicine | 1 | 2010 | 28 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 331 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 170 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2010 | 99 | 0.020 |
Why?
|
| Sulfinpyrazone | 1 | 2009 | 2 | 0.020 |
Why?
|
| Probenecid | 1 | 2009 | 5 | 0.020 |
Why?
|
| Income | 1 | 2010 | 170 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 418 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2010 | 122 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2010 | 127 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 370 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 422 | 0.020 |
Why?
|
| Tobacco Industry | 1 | 2008 | 19 | 0.020 |
Why?
|
| Child Behavior | 1 | 2009 | 64 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2010 | 189 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 205 | 0.020 |
Why?
|
| Age of Onset | 1 | 2008 | 174 | 0.020 |
Why?
|
| Parent-Child Relations | 1 | 2008 | 59 | 0.020 |
Why?
|
| Commerce | 1 | 2008 | 55 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2008 | 42 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 864 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2008 | 70 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 784 | 0.020 |
Why?
|
| Tobacco Products | 1 | 2008 | 80 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 55 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 1105 | 0.020 |
Why?
|
| Epilepsy | 1 | 2008 | 111 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 979 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 754 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2007 | 101 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2006 | 99 | 0.020 |
Why?
|
| Logistic Models | 1 | 2009 | 1277 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 790 | 0.010 |
Why?
|
| SEER Program | 1 | 2005 | 74 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 1119 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 1556 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 110 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2005 | 129 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 117 | 0.010 |
Why?
|
| Hypertension | 1 | 2008 | 588 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 699 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2010 | 5705 | 0.010 |
Why?
|